Roche deal sets up capsid developer Dyno for faster growth, push into more therapeutic areas

Dyno’s latest and largest deal yet built around its AAV capsid platform will afford it further flexibility to grow quickly and explore new diseases for which its technology may be suitable.

Roche (SIX:ROG; OTCQX:RHHBY) will pay an undisclosed amount up front for rights to use the CapsidMap vector design platform from Dyno Therapeutics Inc. to create gene therapies for CNS diseases and liver-directed therapies. Dyno CEO Eric Kelsic declined to give specific terms, although fulfillment of milestones could yield total payments of $1.8 billion...